Company & Sponsor Intelligence
TauRx Therapeutics Ltd
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials4
Recruiting0
Completed3
Countries1
Therapeutic footprint
alzheimersdementia_other
Indexed studies
NCT02245568Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)
alzheimers · United StatesPHASE3
alzheimers · United StatesPHASE3
NCT01626378Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
dementia_other · United StatesPHASE3
dementia_other · United StatesPHASE3
NCT00515333TRx0014 in Patients With Mild or Moderate Alzheimer's Disease
alzheimers · PHASE2
alzheimers · PHASE2
NCT03446001Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment
alzheimers · United StatesPHASE3
alzheimers · United StatesPHASE3
Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →